BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:177Lu-RAD204 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of 177Lu-RAD204\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06305962-2295@assetmemo.bio
DTSTAMP:20261121T010123Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:177Lu-RAD204: Phase 1 readout est. (NCT06305962)
DESCRIPTION:177Lu-RAD204\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: 17
 7Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors\nEstimated primary completi
 on: December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/17
 7lu-rad204#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06305962
URL:https://assetmemo.bio/drug/177lu-rad204#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
